Meda proposes addition of Kimberly Lein-Mathisen and Lillie Valeur to its Board of Directors

– SWEDEN, Solna – Meda AB’s (STO:MEDAA) Nomination Committee proposes the election of Kimberly Lein-Mathisen and Lillie Li Valeur as new Board members. The committee also proposes the re-election of Peter Claesson, Peter von Ehrenheim, Karen Sörensen, Lars Westerberg and Guido Oelkers. The re-appointment of Martin Svalstedt as Chairman of the Board and Luca Rovati as Vice Chairman is also proposed.

The current Board members Tuve Johannesson and Marianne Hamilton have declined to be considered for re-election to the Board.

Kimberly Lein-Mathisen was born in 1972, is an American citizen and holds an MSc and an MBA from Harvard. Kimberly has been CEO of Lilleborg within the Orkla Group for two years and she has 12 years of experience in senior international positions at Eli Lilly, among others as General Manager of the company’s second largest subsidiary, which is located in Germany. Kimberly is an external Board member of NHST Media Group.

Lillie Li Valeur was born in 1970 and is a Chinese citizen, doctor and holds an MBA from the China International Business School. Lillie has been working for 13 years at Arla, and is now Vice President for South East Asia. She has previous experience in the pharmaceutical and OTC business from Novartis and Lundbeck. Lillie is an external Board member of AarhusKarlshamn AB.

The Nomination Committee for the AGM 2015 consists of Evert Carlsson (Swedbank Robur Fonder), Lars Backsell (B&E Participation AB/Flerie Invest AB), Sigieri Diaz Pallavicini (Fidim S.r.l.), Bert Åke Eriksson (Stena Sessan) and Martin Svalstedt (Meda’s Chairman of the Board).

The Nomination Committee’s other proposals concerning the chairman of the meeting, remuneration and the method used to appoint the Nomination Committee will be disclosed on the website and in the notice of the Annual General Meeting.

The Annual General Meeting of Meda AB will be held on May 6, 2015 at 17.00 CET at Meda AB, Pipers väg 2A, Solna, Sweden.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>